Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

113.77 +3.27 (+2.96%)
Streaming Delayed Price Updated: 1:43 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2022. 
Via The Motley Fool
3 Unstoppable Stocks That Could Double in 5 Years
The opportunities for these innovators are tremendous. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
These two drugmakers are growing in prominence. 
Via The Motley Fool
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
  Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading. 
Via Benzinga
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
Exposures COVID-19
Analyst Ratings for Sarepta Therapeutics
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings: 
Via Benzinga
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
Via Benzinga
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
Via Benzinga
Earnings Scheduled For November 2, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
7 Analysts Have This to Say About Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: 
Via Benzinga
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
Via Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
A Trio of Q3 Winners With Room to Run
It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
Via Benzinga
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Duchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating. 
Via Benzinga
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and... 
Via Benzinga
Sarepta Therapeutics: Q2 Earnings Insights
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Sarepta Therapeutics... 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Sarepta Therapeutics Earnings Preview
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Sarepta... 
Via Benzinga
Chevron, Amazon And Some Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones jumping more than 300 points. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Where Sarepta Therapeutics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Apple, Amazon And Some Other Big Stocks Recording Gains On Friday
Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by CCNB shareholders. 
Via Benzinga
Exxon Mobil (XOM) Stock Pops on Record Profits
Exxon Mobil (XOM) stock is rising on Friday following the release of its earnings report for the second quarter of the year. 
Via InvestorPlace
CENN Stock Alert: Cenntro Invests in E-Cargo Designer
Cenntro (CENN) stock is on the move Friday as investors react to news of the electric vehicle (EV) company acquiring a stake in Antric. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.